Lexicon Pharmaceuticals (LXRX) Raised to “Buy” at BidaskClub

BidaskClub upgraded shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) from a hold rating to a buy rating in a research note published on Thursday.

Several other brokerages have also commented on LXRX. Stifel Nicolaus lowered their price objective on shares of Lexicon Pharmaceuticals from $25.00 to $24.00 and set a buy rating for the company in a report on Friday, May 4th. Wedbush raised their price objective on shares of Lexicon Pharmaceuticals from $38.00 to $40.00 and gave the stock an outperform rating in a report on Monday, April 16th. Zacks Investment Research upgraded shares of Lexicon Pharmaceuticals from a sell rating to a hold rating in a report on Tuesday, February 13th. JPMorgan Chase lowered shares of Lexicon Pharmaceuticals from a neutral rating to an underweight rating and lowered their price objective for the stock from $15.00 to $10.00 in a report on Wednesday, February 14th. Finally, Citigroup lowered their price objective on shares of Lexicon Pharmaceuticals from $28.00 to $27.00 and set a buy rating for the company in a report on Friday, May 4th. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and four have issued a buy rating to the company’s stock. The stock has a consensus rating of Hold and a consensus price target of $24.40.

Shares of LXRX opened at $10.01 on Thursday. The company has a current ratio of 2.72, a quick ratio of 2.70 and a debt-to-equity ratio of 8.85. Lexicon Pharmaceuticals has a one year low of $7.67 and a one year high of $18.00.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last issued its quarterly earnings data on Thursday, May 3rd. The biopharmaceutical company reported ($0.40) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.43) by $0.03. Lexicon Pharmaceuticals had a negative net margin of 140.09% and a negative return on equity of 213.32%. The business had revenue of $25.21 million during the quarter, compared to analyst estimates of $25.30 million. During the same period last year, the business posted ($0.33) earnings per share. Lexicon Pharmaceuticals’s quarterly revenue was up 37.8% compared to the same quarter last year. sell-side analysts predict that Lexicon Pharmaceuticals will post -1.33 EPS for the current year.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Wells Fargo & Company MN increased its stake in shares of Lexicon Pharmaceuticals by 27.2% during the third quarter. Wells Fargo & Company MN now owns 112,721 shares of the biopharmaceutical company’s stock valued at $1,385,000 after purchasing an additional 24,131 shares in the last quarter. Malaga Cove Capital LLC increased its stake in shares of Lexicon Pharmaceuticals by 37.5% during the fourth quarter. Malaga Cove Capital LLC now owns 59,387 shares of the biopharmaceutical company’s stock valued at $587,000 after purchasing an additional 16,198 shares in the last quarter. Schwab Charles Investment Management Inc. increased its stake in shares of Lexicon Pharmaceuticals by 5.6% during the third quarter. Schwab Charles Investment Management Inc. now owns 204,129 shares of the biopharmaceutical company’s stock valued at $2,509,000 after purchasing an additional 10,811 shares in the last quarter. Clearbridge LLC increased its stake in shares of Lexicon Pharmaceuticals by 35.8% during the fourth quarter. Clearbridge LLC now owns 1,189,097 shares of the biopharmaceutical company’s stock valued at $11,748,000 after purchasing an additional 313,350 shares in the last quarter. Finally, Aperio Group LLC bought a new position in shares of Lexicon Pharmaceuticals during the fourth quarter valued at approximately $127,000.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.

Analyst Recommendations for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply